HRP20161530T1 - 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori - Google Patents

2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori Download PDF

Info

Publication number
HRP20161530T1
HRP20161530T1 HRP20161530TT HRP20161530T HRP20161530T1 HR P20161530 T1 HRP20161530 T1 HR P20161530T1 HR P20161530T T HRP20161530T T HR P20161530TT HR P20161530 T HRP20161530 T HR P20161530T HR P20161530 T1 HRP20161530 T1 HR P20161530T1
Authority
HR
Croatia
Prior art keywords
pyrrolo
pyridin
methanone
benzo
methyl
Prior art date
Application number
HRP20161530TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephen John Atkinson
Michael David Barker
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
John Liddle
Robert John Sheppard
Ann Louis Walker
Christopher WELLAWAY
David Matthew Wilson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20161530T1 publication Critical patent/HRP20161530T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20161530TT 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori HRP20161530T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors
EP12740581.9A EP2877467B1 (en) 2012-07-26 2012-07-26 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
HRP20161530T1 true HRP20161530T1 (hr) 2017-02-10

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161530TT HRP20161530T1 (hr) 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori

Country Status (22)

Country Link
US (4) US9127003B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2877467B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6063567B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101916443B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104470919B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012386257B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015001545B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2879341C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1118524T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2877467T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2609126T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20161530T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE033294T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014KN02935A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2877467T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2877467T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2877467T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55684B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2611010C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2877467T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (2) SMT201700052T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014015905A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024678A2 (pt) * 2015-05-21 2018-07-31 Glaxosmithkline Intellectual Property Development Limited derivados de benzoimidazol como inibidores de pad4
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
KR102759005B1 (ko) * 2016-02-23 2025-01-23 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
JP6987843B2 (ja) * 2016-07-27 2022-01-05 パドロック・セラピューティクス・インコーポレイテッドPadlock Therapeutics, Inc. Pad4の共有結合性阻害剤
CN110248934B (zh) * 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂
WO2018102262A1 (en) * 2016-12-02 2018-06-07 University Of Massachusetts Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
PT3684767T (pt) * 2017-09-22 2024-07-29 Jubilant Epipad LLC Compostos heterocíclicos como inibidores de pad
KR102782563B1 (ko) * 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
JP7279057B6 (ja) 2017-11-06 2024-02-15 ジュビラント プローデル エルエルシー Pd1/pd-l1活性化の阻害剤としてのピリミジン誘導体
HUE067265T2 (hu) 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
CN110194770B (zh) * 2018-02-26 2022-08-09 药捷安康(南京)科技股份有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
KR20200131845A (ko) 2018-03-13 2020-11-24 주빌런트 프로델 엘엘씨 Pd1/pd-l1 상호작용/활성화 억제제로서의 비사이클릭 화합물
WO2020033520A1 (en) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
EP3833438B1 (en) * 2018-08-08 2024-02-07 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
CN112789087B (zh) * 2018-08-08 2024-08-13 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
WO2020033490A1 (en) 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Substituted thienopyrroles as pad4 inhibitors
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
JP7212781B2 (ja) 2018-12-19 2023-01-25 ディスアーム セラピューティクス, インコーポレイテッド 神経保護剤と組み合わせたsarm1の阻害剤
US20230002328A1 (en) * 2019-07-03 2023-01-05 University Of Massachusetts Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof
TW202115083A (zh) * 2019-09-27 2021-04-16 大陸商南京藥捷安康生物科技有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
KR20220137694A (ko) * 2020-02-06 2022-10-12 브리스톨-마이어스 스큅 컴퍼니 면역억제제로서 유용한 마크로시클릭 pad4 억제제
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
CA3177532A1 (en) 2020-04-30 2021-11-04 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Fapに対する抗体フラグメント
CN116209441A (zh) 2020-09-18 2023-06-02 住友制药株式会社 新型胺衍生物
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2022140428A2 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2023083365A1 (en) 2021-11-15 2023-05-19 Qilu Regor Therapeutics Inc. Pad4 inhibitors and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
KR20250027599A (ko) * 2022-05-26 2025-02-26 셀진 코포레이션 헤테로시클릭 pad4 억제제
TW202434605A (zh) * 2022-11-24 2024-09-01 大陸商蘇州華明道康生物醫藥有限公司 含硒雜環化合物及其用途
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
PL180900B1 (pl) 1995-04-14 2001-04-30 Glaxo Wellcome Inc Inhalator z dozymetrem
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
BR9913888A (pt) * 1998-09-18 2002-01-08 Basf Ag Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
DE60018782T2 (de) * 1999-10-19 2006-04-06 Merck & Co., Inc. Tyrosin kinase inhibitoren
AU777717B2 (en) 1999-12-24 2004-10-28 Aventis Pharma Limited Azaindoles
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
ES2388434T3 (es) 2003-11-03 2012-10-15 Glaxo Group Limited Dispositivo de administración de fluido
JP2007511596A (ja) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
JP2011521961A (ja) 2008-05-28 2011-07-28 ワイス・エルエルシー 3−置換−1H−インドール化合物、mTORキナーゼおよびPI3キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
NZ595819A (en) * 2009-04-02 2013-02-22 Merck Serono Sa DIHYDROOROTATE DEHYDROGENASE INHIBITORS; benzimidazole-4-carboxylic acid
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using

Also Published As

Publication number Publication date
JP6063567B2 (ja) 2017-01-18
KR101916443B1 (ko) 2018-11-08
SI2877467T1 (sl) 2017-02-28
CY1118524T1 (el) 2017-07-12
US10039755B2 (en) 2018-08-07
RU2014152456A (ru) 2016-09-20
US20170119750A1 (en) 2017-05-04
US20150175600A1 (en) 2015-06-25
SMT201700052T1 (it) 2017-03-08
BR112015001545A2 (pt) 2017-07-04
LT2877467T (lt) 2017-01-10
CN104470919A (zh) 2015-03-25
AU2012386257A1 (en) 2015-03-12
PT2877467T (pt) 2017-01-02
DK2877467T3 (en) 2017-02-13
IN2014KN02935A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-08
EP2877467A1 (en) 2015-06-03
KR20150038438A (ko) 2015-04-08
BR112015001545B1 (pt) 2022-07-05
HUE033294T2 (en) 2017-11-28
US20160009716A1 (en) 2016-01-14
US9127003B2 (en) 2015-09-08
AU2012386257B2 (en) 2016-09-08
US20180161316A1 (en) 2018-06-14
SMT201700052B (it) 2017-03-08
CA2879341C (en) 2019-06-11
ES2609126T3 (es) 2017-04-18
JP2015522628A (ja) 2015-08-06
US9833449B2 (en) 2017-12-05
CN104470919B (zh) 2016-07-06
PL2877467T3 (pl) 2017-08-31
US9518054B2 (en) 2016-12-13
EP2877467B1 (en) 2016-11-02
CA2879341A1 (en) 2014-01-30
RU2611010C2 (ru) 2017-02-17
WO2014015905A1 (en) 2014-01-30
RS55684B1 (sr) 2017-07-31

Similar Documents

Publication Publication Date Title
HRP20161530T1 (hr) 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori
FIC20200051I1 (fi) Entrektinibi tai sen tautomeerit tai farmaseuttisesti hyväksyttävät suolat
MX2010005824A (es) Derivados de aminotiazol.
EP2509602A4 (en) Pyrazolopyrimidine and Corresponding Heterocycles as CK2 Inhibitors
WO2008046758A3 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
NZ600840A (en) Indole compound and pharmaceutical use thereof
IL216741A0 (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
IL212250A0 (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
EP2438079A4 (en) NUCLEIC ACID DELIVERY COMPOSITIONS AND METHOD OF USE THEREOF
EP2017263A4 (en) Heteroarylamide derivative of a lower carboxylic acid
IN2012DN03337A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP2549863A4 (en) COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORTATION
RS54413B1 (en) [4- (5-AMINOMETHYL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - [7-FLUORO-1- (2-METHOXY-ETHYL) -4TRIFLUOROMETOXY-1H-INDOL-3-IL] METHANONE AS INHIBITOR MASTOCYT TRIPTASES
EP2771492A4 (en) SCALABLE PROCESS FOR THE MANUFACTURE OF TIN NANOPARTICLES, COMPOSITIONS WITH TIN NANOPARTICLES AND APPLICATIONS THEREWITH
TW200740764A (en) Pyrazolone derivatives
FR2951885B1 (fr) Dispositif d'amplification multi-ports compense en presence de trafic
ZA201200585B (en) "indole derivative and pharmaceutically acceptable salt thereof"
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
MX2007008141A (es) Composicion farmaceutica de sustancias labiles en medio acido.
FR2940116B1 (fr) Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
ZA200902575B (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
MX2011011716A (es) Derivados de isoquinolina novedosos.
EP2475396A4 (en) MANIPULATED MICROPARTICLES FOR THE RELEASE OF MACROMOLECULES
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
IT1391449B1 (it) "sistema di rivestimento"